Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Did Pfizer overpay for the obesity biotech Metsera? It’s probably still too early to tell, but we have some new data this morning.
The need-to-know this morning
Pfizer reported weight-loss results for a monthly GLP-1 obesity injection that it acquired as part of the $10 billion Metsera transaction. The pharma giant also reported fourth-quarter and 2025 earnings.
Merck’s earnings report can be found here. 2026 guidance was slightly below Street consensus.
FDA wants long-term monitoring of autoimmune patients receiving CAR-T
The FDA is advising drug developers to study the long-term effects of using CAR-T to treat patients with autoimmune conditions, out of concern the therapies could cause cancer or fertility issues.Continue to STAT+ to read the full story…